title: Effect of montelukast monotherapy on oxidative stress parameters and DNA damage in children with asthma.
abstract: BACKGROUND
  There is ample knowledge reported in the literature about the role of oxidative stress in asthma pathogenesis. It is also known that the interaction of reactive oxygen species with DNA may result in DNA strand breaks. The aim of this study was to investigate if montelukast monotherapy affects oxidative stress and DNA damage parameters in a population of pediatric asthma patients.
  
  
  METHODS
  Group I consisted of 31 newly diagnosed asthmatic patients not taking any medication, and group II consisted of 32 patients who had been treated with montelukast for at least 6 months. Forty healthy control subjects were also enrolled in the study. Plasma total oxidant status (TOS) and total antioxidant status (TAS) were measured to assess oxidative stress. DNA damage was assessed by means of alkaline comet assay.
  
  
  RESULTS
  The patients in both group I and group II had statistically significant higher plasma TOS (13.1 ± 4 and 11.1 ± 4.1 μmol H2O2 equivalent/liter, respectively) and low TAS levels (1.4 ± 0.5 and 1.5 ± 0.5 mmol Trolox equivalent/liter, respectively) compared with the control group (TOS: 6.3 ± 3.5 μmol H2O2 equivalent/liter and TAS: 2.7 ± 0.6 mmol Trolox equivalent/liter; p < 0.05). DNA damage was 18.2 ± 1.0 arbitrary units (a.u.) in group I, 16.7 ± 8.2 a.u. in group II and 13.7 ± 3.4 a.u. in the control group. There were statistically significant differences only between group I and the control group (p < 0.05).
  
  
  CONCLUSIONS
  According to the findings, montelukast therapy makes only minimal but not statistically significant improvement in all TOS, TAS and DNA damage parameters.
authors: Divisions of Pediatric Allergy and Immunology, Department of Pediatrics, Bezmialem Vakif University Medical Faculty, Istanbul, Turkey.
authors: Fatih
authors: F
authors: Dilek
authors: Emin
authors: E
authors: Ozkaya
authors: Abdurrahim
authors: A
authors: Kocyigit
authors: Mebrure
authors: M
authors: Yazici
authors: Siddika
authors: S
authors: Kesgin
authors: Ahmet Hakan
authors: AH
authors: Gedik
authors: Erkan
authors: E
authors: Cakir
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism; D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism*; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D003521:Cyclopropanes; D004249:DNA Damage; D005260:Female; D006801:Humans; D008297:Male; D018384:Oxidative Stress / Q000187:drug effects; D011804:Quinolines / Q000627:therapeutic use*; D013440:Sulfides
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D000975:Antioxidants; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; C093875:montelukast